View Older Stories View More Recent Stories
-
Adlai Nortye raises $140 million in private placement financing
-
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
-
TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
-
Strong year for hedge funds drives big gains for Wall Street's prime brokerage engine
-
Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline
-
Hedge funds rode buoyant stock market to deliver double-digit gains in 2025, Goldman Sachs says
-
Factbox-Top hedge funds led by D.E.Shaw, Bridgewater and Balyasny deliver big gains in 2025
-
Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1
-
Hedge fund managing partner Dmitry Balyasny taps AI as largest tail risk for 2026
-
Crescent Biopharma raises $185 million, partners with Kelun-Biotech
-
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tu
-
Factbox-How hedge funds performed in a volatile November
-
Balyasny Asset Management up over 15% so far in 2025, says source
-
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
-
Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors
-
Factbox-Some Wall St hedge funds trimmed megacap positions in 3rd quarter
-
US hedge funds trim stakes in 'Magnificent Seven' stocks in third quarter
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Spirit AeroSystems Holdi Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Avalo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Camping World Holdings, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Forterra Closes $238 Million Series C, Cementing Leadership in Autonomy and Interoperable Systems
-
Galecto Announces Acquisition of Damora Therapeutics
-
Factbox-How hedge funds performed in October
-
Citadel's flagship fund gained 1.8% in October, source says
-
Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting
-
Opus Genetics raises $23 million in registered direct offering
-
Opus Genetics Announces $23 Million Registered Direct Offering
-
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
-
Tango Therapeutics raises $225 million in stock offering
-
Tango Therapeutics Announces $225 Million Financing
-
Expedia Group names Rob Bevegni as VP of investor relations
-
Expedia Group Appoints Rob Bevegni as Vice President of Investor Relations
-
Minerva Neurosciences secures up to $200 million for schizophrenia drug trial
-
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and R
-
Lexeo Therapeutics closes $153.8 million public offering and private placement
-
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
-
Lexeo Therapeutics prices $135 million public offering at $8 per share
-
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
-
Lexeo Therapeutics launches stock offering and private placement
-
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
-
Factbox-How hedge funds performed in September
-
Ovid Therapeutics raises up to $175 million in private placement
-
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
-
Howard Cheng Joins Carrick Lane as Partner and Head of Risk
